Annual EBITDA
-$96.80 M
+$83.92 M+46.44%
31 December 2023
Summary:
Sangamo Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$96.80 million, with the most recent change of +$83.92 million (+46.44%) on 31 December 2023. During the last 3 years, it has risen by +$19.38 million (+16.68%). SGMO annual EBITDA is now -30340.25% below its all-time high of -$318.00 thousand, reached on 31 December 1996.SGMO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$12.76 M
+$46.10 M+138.27%
30 September 2024
Summary:
Sangamo Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $12.76 million, with the most recent change of +$46.10 million (+138.27%) on 30 September 2024. Over the past year, it has increased by +$66.95 million (+123.54%). SGMO quarterly EBITDA is now -84.48% below its all-time high of $82.19 million, reached on 31 March 2023.SGMO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$123.99 M
+$66.95 M+35.06%
30 September 2024
Summary:
Sangamo Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$123.99 million, with the most recent change of +$66.95 million (+35.06%) on 30 September 2024. Over the past year, it has dropped by -$35.99 million (-40.90%). SGMO TTM EBITDA is now -6422.15% below its all-time high of -$1.90 million, reached on 31 March 2000.SGMO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.4% | +123.5% | -40.9% |
| 3 y3 years | +16.7% | +129.1% | +27.3% |
| 5 y5 years | -29.4% | +148.7% | -3.2% |
SGMO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +46.4% | -84.5% | +119.3% | -113.0% | +44.6% |
| 5 y | 5 years | -29.4% | +46.4% | -84.5% | +119.3% | -113.0% | +44.6% |
| alltime | all time | <-9999.0% | +46.4% | -84.5% | +119.3% | -6422.1% | +44.6% |
Sangamo Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $12.76 M(-138.3%) | -$123.99 M(-35.1%) |
| June 2024 | - | -$33.34 M(-25.3%) | -$190.93 M(-14.6%) |
| Mar 2024 | - | -$44.65 M(-24.0%) | -$223.64 M(+131.0%) |
| Dec 2023 | -$96.80 M(-46.4%) | -$58.75 M(+8.4%) | -$96.80 M(+10.0%) |
| Sept 2023 | - | -$54.19 M(-17.9%) | -$88.00 M(+5.4%) |
| June 2023 | - | -$66.04 M(-180.4%) | -$83.52 M(+43.5%) |
| Mar 2023 | - | $82.19 M(-264.5%) | -$58.21 M(-67.8%) |
| Dec 2022 | -$180.72 M(+9.1%) | -$49.95 M(+0.5%) | -$180.72 M(+9.0%) |
| Sept 2022 | - | -$49.71 M(+22.1%) | -$165.81 M(+3.7%) |
| June 2022 | - | -$40.73 M(+1.0%) | -$159.94 M(-2.2%) |
| Mar 2022 | - | -$40.32 M(+15.1%) | -$163.62 M(-1.3%) |
| Dec 2021 | -$165.70 M(+42.6%) | -$35.04 M(-20.1%) | -$165.70 M(-2.8%) |
| Sept 2021 | - | -$43.84 M(-1.3%) | -$170.43 M(+34.2%) |
| June 2021 | - | -$44.41 M(+4.7%) | -$127.01 M(+8.3%) |
| Mar 2021 | - | -$42.40 M(+6.6%) | -$117.26 M(+0.9%) |
| Dec 2020 | -$116.18 M(+21.6%) | -$39.77 M(+9301.4%) | -$116.18 M(+61.6%) |
| Sept 2020 | - | -$423.00 K(-98.8%) | -$71.88 M(-26.4%) |
| June 2020 | - | -$34.67 M(-16.1%) | -$97.67 M(+3.4%) |
| Mar 2020 | - | -$41.33 M(-1010.6%) | -$94.50 M(-1.1%) |
| Dec 2019 | -$95.57 M(+27.8%) | $4.54 M(-117.3%) | -$95.57 M(-20.5%) |
| Sept 2019 | - | -$26.22 M(-16.8%) | -$120.19 M(+9.5%) |
| June 2019 | - | -$31.50 M(-25.7%) | -$109.76 M(+13.4%) |
| Mar 2019 | - | -$42.40 M(+111.1%) | -$96.78 M(+29.4%) |
| Dec 2018 | -$74.79 M(+36.3%) | -$20.08 M(+27.3%) | -$74.79 M(+10.0%) |
| Sept 2018 | - | -$15.78 M(-14.8%) | -$68.01 M(+4.9%) |
| June 2018 | - | -$18.52 M(-9.3%) | -$64.85 M(+10.3%) |
| Mar 2018 | - | -$20.41 M(+53.5%) | -$58.78 M(+7.1%) |
| Dec 2017 | -$54.86 M(-23.3%) | -$13.30 M(+5.3%) | -$54.86 M(+7.3%) |
| Sept 2017 | - | -$12.62 M(+1.4%) | -$51.14 M(-11.0%) |
| June 2017 | - | -$12.45 M(-24.5%) | -$57.47 M(-19.7%) |
| Mar 2017 | - | -$16.49 M(+72.2%) | -$71.62 M(+0.1%) |
| Dec 2016 | -$71.56 M(+56.0%) | -$9.58 M(-49.5%) | -$71.56 M(-7.6%) |
| Sept 2016 | - | -$18.95 M(-28.7%) | -$77.41 M(+9.3%) |
| June 2016 | - | -$26.59 M(+61.8%) | -$70.83 M(+26.0%) |
| Mar 2016 | - | -$16.44 M(+6.5%) | -$56.23 M(+22.6%) |
| Dec 2015 | -$45.87 M(+74.9%) | -$15.43 M(+24.8%) | -$45.87 M(+32.0%) |
| Sept 2015 | - | -$12.37 M(+3.1%) | -$34.76 M(+16.3%) |
| June 2015 | - | -$12.00 M(+97.5%) | -$29.89 M(+20.5%) |
| Mar 2015 | - | -$6.07 M(+40.6%) | -$24.82 M(-5.4%) |
| Dec 2014 | -$26.23 M(+0.4%) | -$4.32 M(-42.4%) | -$26.23 M(-12.4%) |
| Sept 2014 | - | -$7.50 M(+8.4%) | -$29.96 M(+5.2%) |
| June 2014 | - | -$6.92 M(-7.6%) | -$28.48 M(+6.0%) |
| Mar 2014 | - | -$7.49 M(-7.0%) | -$26.87 M(+2.8%) |
| Dec 2013 | -$26.14 M(+21.4%) | -$8.05 M(+33.7%) | -$26.14 M(+22.7%) |
| Sept 2013 | - | -$6.02 M(+13.4%) | -$21.30 M(+1.8%) |
| June 2013 | - | -$5.31 M(-21.4%) | -$20.91 M(-1.3%) |
| Mar 2013 | - | -$6.76 M(+110.6%) | -$21.18 M(-1.7%) |
| Dec 2012 | -$21.54 M(-38.8%) | -$3.21 M(-43.1%) | -$21.54 M(-12.2%) |
| Sept 2012 | - | -$5.64 M(+1.0%) | -$24.53 M(-13.3%) |
| June 2012 | - | -$5.58 M(-21.6%) | -$28.30 M(-13.8%) |
| Mar 2012 | - | -$7.12 M(+14.8%) | -$32.85 M(-6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$35.17 M(+45.0%) | -$6.20 M(-34.2%) | -$35.17 M(-5.3%) |
| Sept 2011 | - | -$9.41 M(-7.0%) | -$37.14 M(+2.4%) |
| June 2011 | - | -$10.12 M(+7.3%) | -$36.27 M(+21.5%) |
| Mar 2011 | - | -$9.44 M(+15.6%) | -$29.86 M(+23.1%) |
| Dec 2010 | -$24.26 M(+28.8%) | -$8.16 M(-4.5%) | -$24.26 M(+32.0%) |
| Sept 2010 | - | -$8.54 M(+130.4%) | -$18.38 M(+26.8%) |
| June 2010 | - | -$3.71 M(-3.5%) | -$14.49 M(-8.2%) |
| Mar 2010 | - | -$3.84 M(+68.4%) | -$15.79 M(-16.1%) |
| Dec 2009 | -$18.83 M(-24.2%) | -$2.28 M(-51.0%) | -$18.83 M(+1.2%) |
| Sept 2009 | - | -$4.66 M(-7.1%) | -$18.61 M(-7.9%) |
| June 2009 | - | -$5.01 M(-27.2%) | -$20.19 M(-12.4%) |
| Mar 2009 | - | -$6.88 M(+234.5%) | -$23.04 M(-7.3%) |
| Dec 2008 | -$24.85 M(+1.4%) | -$2.06 M(-67.1%) | -$24.86 M(-18.0%) |
| Sept 2008 | - | -$6.25 M(-20.5%) | -$30.32 M(+6.9%) |
| June 2008 | - | -$7.86 M(-9.6%) | -$28.36 M(+7.7%) |
| Mar 2008 | - | -$8.69 M(+15.6%) | -$26.34 M(+11.4%) |
| Dec 2007 | -$24.50 M(+18.2%) | -$7.52 M(+75.3%) | -$23.65 M(-8.8%) |
| Sept 2007 | - | -$4.29 M(-26.5%) | -$25.94 M(+2.6%) |
| June 2007 | - | -$5.84 M(-2.8%) | -$25.29 M(+7.5%) |
| Mar 2007 | - | -$6.01 M(-38.7%) | -$23.53 M(+13.6%) |
| Dec 2006 | -$20.73 M(+56.3%) | -$9.81 M(+169.2%) | -$20.70 M(+50.6%) |
| Sept 2006 | - | -$3.64 M(-10.5%) | -$13.75 M(-0.5%) |
| June 2006 | - | -$4.07 M(+27.9%) | -$13.82 M(+5.9%) |
| Mar 2006 | - | -$3.18 M(+11.8%) | -$13.06 M(-1.5%) |
| Dec 2005 | -$13.26 M(+0.7%) | -$2.85 M(-23.4%) | -$13.26 M(-2.6%) |
| Sept 2005 | - | -$3.72 M(+12.3%) | -$13.61 M(-4.4%) |
| June 2005 | - | -$3.31 M(-2.4%) | -$14.24 M(+101.2%) |
| Mar 2005 | - | -$3.39 M(+5.8%) | -$7.08 M(+11.0%) |
| Dec 2004 | -$13.17 M(+37.2%) | -$3.20 M(-26.3%) | -$6.38 M(+30.9%) |
| Sept 2004 | - | -$4.35 M(-212.7%) | -$4.87 M(+132.6%) |
| June 2004 | - | $3.86 M(-243.7%) | -$2.09 M(-78.3%) |
| Mar 2004 | - | -$2.68 M(+58.2%) | -$9.65 M(+0.9%) |
| Dec 2003 | -$9.60 M(-65.6%) | -$1.70 M(+8.1%) | -$9.57 M(+44.4%) |
| Sept 2003 | - | -$1.57 M(-57.6%) | -$6.63 M(-74.6%) |
| June 2003 | - | -$3.70 M(+42.5%) | -$26.12 M(+0.3%) |
| Mar 2003 | - | -$2.60 M(-308.8%) | -$26.05 M(-6.6%) |
| Dec 2002 | -$27.89 M(+151.9%) | $1.24 M(-105.9%) | -$27.89 M(-5.2%) |
| Sept 2002 | - | -$21.06 M(+479.4%) | -$29.42 M(+118.1%) |
| June 2002 | - | -$3.63 M(-18.0%) | -$13.49 M(+10.6%) |
| Mar 2002 | - | -$4.43 M(+1428.6%) | -$12.19 M(+24.2%) |
| Dec 2001 | -$11.07 M(+52.7%) | -$290.00 K(-94.3%) | -$9.81 M(-15.7%) |
| Sept 2001 | - | -$5.13 M(+119.2%) | -$11.64 M(+41.1%) |
| June 2001 | - | -$2.34 M(+13.7%) | -$8.25 M(+11.4%) |
| Mar 2001 | - | -$2.06 M(-2.8%) | -$7.41 M(+2.2%) |
| Dec 2000 | -$7.25 M(+126.6%) | -$2.12 M(+21.9%) | -$7.25 M(+41.2%) |
| Sept 2000 | - | -$1.74 M(+16.1%) | -$5.13 M(+51.1%) |
| June 2000 | - | -$1.50 M(-21.3%) | -$3.40 M(+78.7%) |
| Mar 2000 | - | -$1.90 M | -$1.90 M |
| Dec 1999 | -$3.20 M(-7.5%) | - | - |
| Dec 1998 | -$3.46 M(+157.1%) | - | - |
| Dec 1997 | -$1.34 M(+323.0%) | - | - |
| Dec 1996 | -$318.00 K | - | - |
FAQ
- What is Sangamo Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual EBITDA year-on-year change?
- What is Sangamo Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly EBITDA year-on-year change?
- What is Sangamo Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM EBITDA year-on-year change?
What is Sangamo Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SGMO is -$96.80 M
What is the all time high annual EBITDA for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$318.00 K
What is Sangamo Therapeutics annual EBITDA year-on-year change?
Over the past year, SGMO annual earnings before interest, taxes, depreciation & amortization has changed by +$83.92 M (+46.44%)
What is Sangamo Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SGMO is $12.76 M
What is the all time high quarterly EBITDA for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $82.19 M
What is Sangamo Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SGMO quarterly earnings before interest, taxes, depreciation & amortization has changed by +$66.95 M (+123.54%)
What is Sangamo Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SGMO is -$123.99 M
What is the all time high TTM EBITDA for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.90 M
What is Sangamo Therapeutics TTM EBITDA year-on-year change?
Over the past year, SGMO TTM earnings before interest, taxes, depreciation & amortization has changed by -$35.99 M (-40.90%)